Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with inflammatory bowel disease after three doses of COVID-19 vaccine: a prospective multicentre cohort study (CLARITY)

Autor: Liu, Z, Le, K, Zhou, X, Alexander, J, Lin, S, Bewshea, C, Chanchlani, N, Nice, R, McDonald, T, Lamb, C, Sebastian, S, Kok, K, Lees, C, Hart, A, Pollok, R, Boyton, R, Altmann, DM, Pollock, KM, Goodhand, J, Kennedy, N, Ahmad, T, Powell, N

Background: Anti-tumour necrosis factor (TNF) drugs such as infliximab are associated with attenuated antibody responses after COVID-19 vaccination. It is unknown how infliximab impacts vaccine-induced serological responses against highly transmissib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::be8005ae711ecf2c0960167252029a8a
http://hdl.handle.net/10044/1/100318

Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection

Autor: Milighetti, M, Peng, Y, Tan, C, Mark, M, Nageswaran, G, Byrne, S, Ronel, T, Peacock, T, Mayer, A, Chandran, A, Rosenheim, J, Whelan, M, Yao, X, Liu, G, Felce, SL, Dong, T, Mentzer, AJ, Knight, JC, Balloux, F, Greenstein, E, Reich-Zeliger, S, Pade, C, Gibbons, JM, Semper, A, Brooks, T, Otter, A, Altmann, DM, Boyton, RJ, Maini, MK, McKnight, A, Manisty, C, Treibel, TA, Moon, JC, COVIDsortium Investigators, Noursadeghi, M, Chain, B

Publikováno v: iScience. :106937

T cell responses precede antibody and may provide early control of infection. We analyzed the clonal basis of this rapid response following SARS-COV-2 infection. We applied T cell receptor (TCR) sequencing to define the trajectories of individual T c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::020f346e505bd879820c95087a0edf48
https://doi.org/10.1016/j.isci.2023.106937

Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring AMR bacterial pneumonia

Autor: Gregorova, M, Morse, D, Brignoli, T, Steventon, J, Hamilton, F, Albur, M, Arnold, D, Thomas, M, Halliday, A, Baum, H, Rice, C, Avison, MB, Davidson, AD, Santopaolo, M, Oliver, E, Goenka, A, Finn, A, Wooldridge, L, Amulic, B, Boyton, RJ, Altmann, DM, Butler, DK, McMurray, C, Stockton, J, Nicholls, S, Cooper, C, Loman, N, Cox, MJ, Rivino, L, Massey, RC

Publikováno v: Gregorova, M, Morse, D, Brignoli, T, Steventon, J, Hamilton, F, Albur, M, Arnold, D, Thomas, M, Halliday, A, Baum, H, Rice, C, Avison, M B, Davidson, A D, Santopaolo, M, Oliver, E, Goenka, A, Finn, A, Wooldridge, L, Amulic, B, Boyton, R J, Altmann, D M, Butler, D K, McMurray, C, Stockton, J, Nicholls, S, Cooper, C, Loman, N, Cox, M J, Rivino, L & Massey, R C 2020, ' Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring AMR bacterial pneumonia ', eLife, vol. 9, e63430 . https://doi.org/10.7554/eLife.63430

Here we describe the case of a COVID-19 patient who developed recurring ventilator-associated pneumonia caused by Pseudomonas aeruginosa that acquired increasing levels of antimicrobial resistance (AMR) in response to treatment. Metagenomic analysis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::8c4bc002b989c9b057d52abd1dfe4714
https://research-information.bris.ac.uk/ws/files/263283465/elife_63430_v2.pdf

Human type II collagen is processed in lysosomal compartments of macrophages for presentation of the glycosylated arthritogenic epitope hCII259–273 to CD4 T cells in HLA-DR1 transgenic mice

Autor: von Delwig, A, Altmann, DM, Isaacs, JD, Holmdahl, R, McKie, N, Robinson, JH

Publikováno v: Arthritis Research & Therapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmc_________::cbc175d3aa064a1681d864a3592b565d
http://europepmc.org/articles/PMC2834013

The immunology of sepsis.

Autor: Sriskandan, S, Altmann, DM

Publikováno v: Journal of Pathology; Jan2008, Vol. 214 Issue 2, p211-223, 13p